Role of radiofrequency ablation in the treatment of liver metastases from colorectal cancer: Pooled analysis of randomized clinical trials.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14557-e14557
Author(s):  
Fabrizio Drudi ◽  
Emiliano Tamburini ◽  
Manuela Fantini ◽  
Antonio Polselli ◽  
Lucia Stocchi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Radiofrequency Ablation ◽  
Liver Metastases ◽  
Randomized Clinical Trials ◽  
Pooled Analysis

Cetuximab or Panitumumab versus Bevacizumab in the treatment of first line RAS wild type colorectal cancer: pooled analysis of randomized clinical trials.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e14634-e14634
Author(s):  
Emiliano Tamburini ◽  
Britt Rudnas ◽  
Mario Nicolini ◽  
Stefania Nicoletti ◽  
Manuela Fantini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Pooled Analysis ◽  
Wild Type ◽  
First Line

Chemotherapy in metastatic hormone-naïve prostate cancer: Pooled analysis of randomized clinical trials.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 259-259 ◽  
Author(s):  
Paolo Fabbri ◽  
Lucia Stocchi ◽  
Stefania Nicoletti ◽  
Fabrizio Drudi ◽  
Emiliano Tamburini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Clinical Trials ◽  
Confidence Interval ◽  
Preliminary Analysis ◽  
Randomized Clinical Trials ◽  
Pooled Analysis ◽  
Hazard Ratio ◽  
Androgen Blockade

259 Background: To assess the role of chemotherapy in metastatic, hormone-naïve prostate cancer, we presents the preliminary data of a pooled analysis comparing the outcome of patients with metastatic hormone-naïve prostate cancer. Methods: A pooled analysis of the outcome of randomized clinical trials approaching the role of docetaxel in metastatic hormone-naïve prostate cancer was performed using a random effect model. The final outcome of all the patients enrolled into the trials was the primary end point of our analysis. The pooled final result was reported as pooled Hazard Ratio and 95% Confidence Interval. The between-the trials heterogeneity was assessed using the I2 test. An α-error of 5% was identified as index of statistical significance. Overall survival of the entire population enrolled into the trials was the outcome of the preliminary analysis, while no subgroup analysis was performed in this preliminary phase of a multi-steps analysis. Results: Three trials (the CHAARTED, the STAMPEDE and the GETUG-AFU 15 trial) were considered eligible and included into the analysis. A pooled Hazard Ratio of 0.76 (95% Confidence Interval of 0.59-0.98, p = 0.037) was detected for overall survival, with an I2 of 67.8. The pooled datum was obtained observed the outcome of 951 patients treated with docetaxel plus androgen blockade and 1338 with androgen blockade alone. Conclusions: Although the between-the-trials heterogeneity seems to suggest caution in the final interpretation of the results, a significant reduction of the risk of death can be obtained with docetaxel in the treatment of metastatic hormone-naïve prostate cancer. Our preliminary analysis, including all the patients with metastatic hormone-naïve prostate cancer, seems to suggest a role of docetaxel in all the patients with metastatic disease; further data are probably needed to detect its role in some different subclasses of patients (patients with high burden of the disease, fit or unfit patients, elderly patients).

Prognostic role of 25-hydroxyvitamin D in patients with liver metastases from colorectal cancer treated with radiofrequency ablation

2016 ◽  
Vol 31 (8) ◽  
pp. 1483-1488 ◽  
Author(s):  
Antonio Facciorusso ◽  
Valentina Del Prete ◽  
Nicola Muscatiello ◽  
Nicola Crucinio ◽  
Michele Barone
Keyword(s):  
Colorectal Cancer ◽  
Radiofrequency Ablation ◽  
Liver Metastases ◽  
Prognostic Role ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

Radiofrequency ablation of liver metastases from colorectal cancer

2007 ◽  
Vol 28 (S 1) ◽  
Author(s):  
J Genov ◽  
N Grigorov ◽  
R Mitova ◽  
B Golemanov ◽  
L Dinkov ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Radiofrequency Ablation ◽  
Liver Metastases
Sign in / Sign up

Export Citation Format

Share Document